Matches in SemOpenAlex for { <https://semopenalex.org/work/W2809866417> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- W2809866417 endingPage "S31" @default.
- W2809866417 startingPage "S30" @default.
- W2809866417 abstract "Lung cancer has high rates of mortality worldwide and within lung cancer subtypes Non-small cell lung cancer (NSCLC) is the most frequent. Cancer survival rates have improved during the past decades, however the advances accomplished in other malignancies have yet been achieved in lung cancer. Crizotinib has many advantages in the treatment of locally advanced or metastatic NSCLC that is anaplastic lymphoma kinase (ALK)-positive compared to other available therapies. The aim of this study was to evaluate the cost-effectiveness of crizotinib compared with the standard chemotherapy for the treatment for second and third line of treatment in advanced or metastatic NSCLC in the public healthcare system in Ecuador. A Markov model was developed based on overall survival (OS) reported in Shaw 2011 study. The dosing schedule of oral crizotinib was 250 mg twice daily and for standard chemotherapy it was pemetrexed, 500 mg/m², plus cisplatin, 75 mg/m², or carboplatin every 3 weeks. All costs were taken from the Ecuadorian Reference Costs (2017). Total costs were crizotinib (60,447.2 USD), pemetrexed + carboplatin (7,780.8 USD) and pemetrexed + cisplatin (6,592.7 USD). The efficacy was determined by one-year and 2-year OS. The ICER of crizotinib was 2,0253.08 USD compared to pemetrexed + carboplatin and 207,132.69 USD per life year compared to pemetrexed + cisplatin. At two years, the ICER for patients treated with crizotinib vs. pemetrexed + carboplatin was 122,480.0 USD and for crizotinib vs. pemetrexed + cisplatin 125,243.02 USD per life year. The values of ICERs obtained at the second year were acceptable in the Ecuadorian health system." @default.
- W2809866417 created "2018-07-10" @default.
- W2809866417 creator A5036460885 @default.
- W2809866417 creator A5041168917 @default.
- W2809866417 creator A5062026199 @default.
- W2809866417 creator A5088714969 @default.
- W2809866417 date "2018-05-01" @default.
- W2809866417 modified "2023-10-04" @default.
- W2809866417 title "Cost-Effectiveness of Crizotinib for Second and Third-Line Treatment of Non-Small Cell Lung Cancer in Ecuador" @default.
- W2809866417 doi "https://doi.org/10.1016/j.jval.2018.04.194" @default.
- W2809866417 hasPublicationYear "2018" @default.
- W2809866417 type Work @default.
- W2809866417 sameAs 2809866417 @default.
- W2809866417 citedByCount "0" @default.
- W2809866417 crossrefType "journal-article" @default.
- W2809866417 hasAuthorship W2809866417A5036460885 @default.
- W2809866417 hasAuthorship W2809866417A5041168917 @default.
- W2809866417 hasAuthorship W2809866417A5062026199 @default.
- W2809866417 hasAuthorship W2809866417A5088714969 @default.
- W2809866417 hasBestOaLocation W28098664171 @default.
- W2809866417 hasConcept C117643217 @default.
- W2809866417 hasConcept C126322002 @default.
- W2809866417 hasConcept C143998085 @default.
- W2809866417 hasConcept C2776232967 @default.
- W2809866417 hasConcept C2776256026 @default.
- W2809866417 hasConcept C2776694085 @default.
- W2809866417 hasConcept C2777240266 @default.
- W2809866417 hasConcept C2778239845 @default.
- W2809866417 hasConcept C2779422266 @default.
- W2809866417 hasConcept C2781451048 @default.
- W2809866417 hasConcept C71924100 @default.
- W2809866417 hasConceptScore W2809866417C117643217 @default.
- W2809866417 hasConceptScore W2809866417C126322002 @default.
- W2809866417 hasConceptScore W2809866417C143998085 @default.
- W2809866417 hasConceptScore W2809866417C2776232967 @default.
- W2809866417 hasConceptScore W2809866417C2776256026 @default.
- W2809866417 hasConceptScore W2809866417C2776694085 @default.
- W2809866417 hasConceptScore W2809866417C2777240266 @default.
- W2809866417 hasConceptScore W2809866417C2778239845 @default.
- W2809866417 hasConceptScore W2809866417C2779422266 @default.
- W2809866417 hasConceptScore W2809866417C2781451048 @default.
- W2809866417 hasConceptScore W2809866417C71924100 @default.
- W2809866417 hasLocation W28098664171 @default.
- W2809866417 hasOpenAccess W2809866417 @default.
- W2809866417 hasPrimaryLocation W28098664171 @default.
- W2809866417 hasRelatedWork W2046767112 @default.
- W2809866417 hasRelatedWork W2358450743 @default.
- W2809866417 hasRelatedWork W2378767654 @default.
- W2809866417 hasRelatedWork W2471989939 @default.
- W2809866417 hasRelatedWork W2516942920 @default.
- W2809866417 hasRelatedWork W2658569466 @default.
- W2809866417 hasRelatedWork W2782109468 @default.
- W2809866417 hasRelatedWork W2811209142 @default.
- W2809866417 hasRelatedWork W3032772405 @default.
- W2809866417 hasRelatedWork W3197633853 @default.
- W2809866417 hasVolume "21" @default.
- W2809866417 isParatext "false" @default.
- W2809866417 isRetracted "false" @default.
- W2809866417 magId "2809866417" @default.
- W2809866417 workType "article" @default.